Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Publication/Presentation Date

11-2025

Volume

146

Issue

1

First Page

5814

Last Page

5814

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division

Document Type

Article

Share

COinS